Brief: Coherus BioSciences Q2 Adjusted EPS USD 116077710

Coherus Oncology

07/08/2025 21:42

Corrects Adjusted EPS in Key Details table to -$0.34

Overview

Coherus Q2 2025 LOQTORZI net revenue rises 36% to $10 mln

Sales beat analyst expectations, driven by higher demand and inventory restocking

Coherus completed UDENYCA divestiture, boosting cash and reducing obligations

Outlook

Coherus on track for data readouts for CHS-114 and casdozokitug in 1H 2026

Company plans to combine LOQTORZI with pipeline candidates for new indications

Coherus aims for external partnerships to expand product labels

Company has a cash runway through 2026

Result Drivers

LOQTORZI DEMAND - Higher patient demand and inventory restocking drove 36% revenue growth for LOQTORZI in Q2 2025

NCCN GUIDELINES - Revision in NCCN guidelines granting LOQTORZI preferred status for NPC indication contributed to strong demand growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$10.25 mln
$10.10 mln (5 Analysts)
Q2 Adjusted EPS
Miss
-$0.34
-$0.32 (2 Analysts)
Q2 Adjusted Net Income
Miss
-$39.03 mln
-$38.70 mln (1 Analyst)
Q2 Net Income
$297.77 mln
Q2 Operating Income
-$45.49 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 85.9% above its August 6 closing price of $0.92

Press Release: ID:nGNX8DsbmY

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)